| Objective To investigate the clinical efficacy of exenatide combined with insulin glarginein type2diabetes patients with obesity.Methods Select30patients with newly diagnosed type2diabetes with obese as theresearch object.Patients enrolled in60minutes before breakfast and dinner subcutaneousinjection of exenatide, and fixed bedtime subcutaneous injection of insulin glargine.Thestarting dose of exenatide is5ug,twice a day,after4weeks the dose was increased to10ug,twice a day.The starting dose of insulin glargine is0.2U/kg·d, FPG4.5-6.5mmol/Lfor the target value, each exceed the target value1mmol/insulin glargine increase1u,hypoglycemia (<3.9mmol/L), a decrease of2-4U, adjust doses every3-4days. Maintain thedose of insulin glargine when Fasting blood glucose control.All patients with diabeticstandard caloric diet and exercise as a basis for the treatment.After24weeks,Self-controlled method to observe the changes of blood glucose, glycosylated hemoglobin(HbAlc), HOMA-IR, HOMA-β, body mass index (BMI), waist circumference (WC), bloodpressure, cholesterol and other indicators.Results After treatment, fasting plasma glucose (FPG),2hours postprandial the glycemic(2hPG), HbAlc, WC, BMI, HOMA-IR,systolic blood pressure (SBP), triglycerides (TG),cholesterol (TC) and low density lipoprotein (LDL-C) were significantly decreased, andthe difference was statistically significant (P<0.01). HOMA-β was significantly higher thanthat before treatment, the difference was statistically significant (P<0.01). Course oftreatment,6patients had mild gastrointestinal side effects like nausea,bloating,with thetime of treatment can be improved and tolerated;4cases of hypoglycemia in patients withspontaneous remission after eating,no partners consciousness obstacles severe hypoglycemia events.Conclusions The therapy with exenatide and insulin glargine insulin could effectivelycontrol blood glucose,significantly improve β-cell functionin and reduce weight in newlydiagnosed T2DM patients with obesity. |
